Repligen Corporation $RGEN Holdings Raised by Artemis Investment Management LLP

Key Points

• Artemis Investment Management increased its stake in Repligen by 18.3% to 410,369 shares (about 0.73% of the company) valued at $67.24 million, and institutional investors now own roughly 97.64% of the stock.
• Repligen beat Q4 expectations with $0.49 EPS versus a $0.44 consensus and revenue of $197.9 million (up 18.1% YoY vs $192.2M est), and set FY 2026 guidance of $1.93–$2.01 EPS (analyst consensus 1.97).
• Analyst sentiment is mixed but generally positive — consensus rating "Moderate Buy" with a $170.25 target — while the stock trades at a $6.61 billion market cap and a high P/E of about 137.9.

Artemis Investment Management LLP lifted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 410,369 shares of the biotechnology company's stock after purchasing an additional 63,583 shares during the quarter. Artemis Investment Management LLP owned about 0.73% of Repligen worth $67,243,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Kornitzer Capital Management Inc. KS raised its stake in shares of Repligen by 7.0% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 83,780 shares of the biotechnology company's stock valued at $13,728,000 after purchasing an additional 5,500 shares in the last quarter. Horizon Investments LLC bought a new stake in shares of Repligen during the fourth quarter valued at about $84,000. Fifth Third Bancorp raised its stake in shares of Repligen by 19.7% during the fourth quarter. Fifth Third Bancorp now owns 3,772 shares of the biotechnology company's stock valued at $618,000 after purchasing an additional 622 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 10.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company's stock valued at $173,360,000 after purchasing an additional 101,062 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its stake in shares of Repligen by 8.2% during the fourth quarter. Oppenheimer & Co. Inc. now owns 1,623 shares of the biotechnology company's stock valued at $266,000 after purchasing an additional 123 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Trading Down 0.9%

Shares of NASDAQ RGEN opened at $117.20 on Friday. The stock has a market cap of $6.61 billion, a price-to-earnings ratio of 137.88, a PEG ratio of 2.31 and a beta of 1.09. The business has a 50 day simple moving average of $121.56 and a 200 day simple moving average of $144.73. Repligen Corporation has a 52 week low of $109.50 and a 52 week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. During the same period in the previous year, the company earned $0.44 EPS. The company's revenue for the quarter was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, research analysts predict that Repligen Corporation will post 1.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Weiss Ratings cut shares of Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, March 3rd. HC Wainwright boosted their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, March 23rd. Barclays dropped their price target on shares of Repligen from $175.00 to $145.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 14th. KeyCorp reiterated an "overweight" rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, Wells Fargo & Company dropped their price target on shares of Repligen from $190.00 to $180.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and a consensus target price of $170.25.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.